Corsair Pharma is developing transformative solutions to improve the therapeutic profile of medications and provide superior treatment options for patients. The company’s first product candidate is a prodrug of treprostinil delivered on a proprietary transdermal patch to treat pulmonary arterial hypertension (PAH).
Corsair also believes that their transdermal patch has the potential in other forms of pulmonary hypertension. The company has a strategic partnership with United Therapeutics, the market leader in PAH therapies.
Corsair has developed a proprietary patch designed to be safe, effective and convenient. The patch is intended to provide consistent blood levels of treprostinil comparable to an infusion pump by delivering an inactive prodrug, which crosses the skin, enters the blood, and converts rapidly to treprostinil in the liver. A transdermal patch alleviates the need for central vein catheter placement or continuous subcutaneous infusion.
Since the prodrug is inactive, the patch is also expected to mitigate the issues of infusion site pain and infusion site reactions attributed to trepostinil on-target effects. The product candidate is designed to allow physicians greater flexibility in mono- and combination therapy and to provide patients a well-established, safe, and effective therapeutic choice that is better tolerated with fewer side effects.
Corsair intends to initiate Phase 1 clinical trial to evaluate PK and safety/tolerability of the candidate product in the second half of 2024.